Last reviewed · How we verify
NCT05707897
A Food Effect Study of TS-142 in Healthy Subjects
Phase 1 trial testing TS-142 10 mg in Effect of Food in 12 participants. Completed in 20 March 2023.
20 March 2023
Quick facts
| Lead sponsor | Taisho Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 15 February 2023 |
| Primary completion | 20 March 2023 |
| Estimated completion | 20 March 2023 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- TS-142 10 mg — full drug profile →
Conditions studied
- Effect of Food — all drugs for Effect of Food →
Sponsor
Taisho Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 39, male only, with Effect of Food. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study to assess the food effect of TS-142 preliminary market formulation tablet in healthy subjects
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia.
Kamigaso S, Konno Y, Hikichi H, Kambe D, et al · · 2026 · cited 1× · PMID 41622624 · DOI 10.1002/prp2.70217
Verify or expand the search:
- PubMed search for NCT05707897
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TS-142 10 mg
Trials testing the same drug.
- NCT05461352 — Long-Term Study of TS-142 in Patients with Insomnia · Phase 3 · completed
- NCT05453136 — Phase III Study of TS-142 in Patients with Insomnia · Phase 3 · completed
Other recruiting trials for Effect of Food
Currently open trials in the same condition.
- NCT06662214 — Nutrient Profile and Muscle Protein Synthesis in Response to Corn Bread Made From Refined Versus Whole Grain Maize Flour · NA · recruiting
- NCT06489886 — Nutrient and Hormonal Profile and Muscle Protein Synthesis Response to Consuming Chicken · NA · active not recruiting
Other Taisho Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07285291 — A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders · Phase 3 · recruiting
- NCT07231029 — A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment · Phase 1 · recruiting
- NCT07285304 — A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis · Phase 3 · recruiting
- NCT07084961 — A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects · Phase 1 · completed
- NCT06849778 — An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05707897 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taisho Pharmaceutical Co., Ltd.
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05707897.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing